JP2012502006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502006A5 JP2012502006A5 JP2011525556A JP2011525556A JP2012502006A5 JP 2012502006 A5 JP2012502006 A5 JP 2012502006A5 JP 2011525556 A JP2011525556 A JP 2011525556A JP 2011525556 A JP2011525556 A JP 2011525556A JP 2012502006 A5 JP2012502006 A5 JP 2012502006A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- imidazol
- dione
- phenyl
- imidazolidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, hydroxyl Chemical group 0.000 claims description 115
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 150000001875 compounds Chemical class 0.000 claims description 52
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- OHGGDDBGUDKOBT-UHFFFAOYSA-N 5-(2-chlorophenyl)-1-(3-imidazol-1-ylpropyl)imidazolidine-2,4-dione Chemical compound ClC1=CC=CC=C1C1C(=O)NC(=O)N1CCCN1C=NC=C1 OHGGDDBGUDKOBT-UHFFFAOYSA-N 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 230000000949 anxiolytic effect Effects 0.000 claims description 2
- 229940005530 anxiolytics Drugs 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229910052979 sodium sulfide Inorganic materials 0.000 claims description 2
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010019375 Helicobacter infections Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000001771 impaired effect Effects 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 3
- 125000005133 alkynyloxy group Chemical group 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 230000008569 process Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000004001 thioalkyl group Chemical group 0.000 claims 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims 2
- 208000023697 ABri amyloidosis Diseases 0.000 claims 2
- 208000017227 ADan amyloidosis Diseases 0.000 claims 2
- 108010022752 Acetylcholinesterase Proteins 0.000 claims 2
- 102000012440 Acetylcholinesterase Human genes 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000012639 Balance disease Diseases 0.000 claims 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 206010061825 Duodenal neoplasm Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims 2
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims 2
- 208000027747 Kennedy disease Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 206010037779 Radiculopathy Diseases 0.000 claims 2
- 206010054184 Small intestine carcinoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 2
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims 2
- 229940022698 acetylcholinesterase Drugs 0.000 claims 2
- 230000037424 autonomic function Effects 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 230000033228 biological regulation Effects 0.000 claims 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000003210 demyelinating effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 201000000312 duodenum cancer Diseases 0.000 claims 2
- 230000008482 dysregulation Effects 0.000 claims 2
- 230000037149 energy metabolism Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000000052 gastrinoma Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 230000013632 homeostatic process Effects 0.000 claims 2
- 230000003054 hormonal effect Effects 0.000 claims 2
- 230000028996 humoral immune response Effects 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 208000000509 infertility Diseases 0.000 claims 2
- 230000036512 infertility Effects 0.000 claims 2
- 231100000535 infertility Toxicity 0.000 claims 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 claims 2
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000005012 migration Effects 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- NITUEMISTORFON-PPFXTMJRSA-N (2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-aminopropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@@H](C)N)C(C)C)C(C)C)C1=CC=CC=C1 NITUEMISTORFON-PPFXTMJRSA-N 0.000 claims 1
- SOCSUCKHKHAOMU-UHFFFAOYSA-N 1'-(3h-benzimidazol-5-yl)spiro[1,3-dihydroindene-2,5'-imidazolidine]-2',4'-dione Chemical compound C1=C2NC=NC2=CC(N2C3(CC4=CC=CC=C4C3)C(=O)NC2=O)=C1 SOCSUCKHKHAOMU-UHFFFAOYSA-N 0.000 claims 1
- HQTRUHWLKNRAGK-UHFFFAOYSA-N 1-(3-imidazol-1-ylpropyl)-5-(4-propoxyphenyl)imidazolidine-2,4-dione Chemical compound C1=CC(OCCC)=CC=C1C1C(=O)NC(=O)N1CCCN1C=NC=C1 HQTRUHWLKNRAGK-UHFFFAOYSA-N 0.000 claims 1
- XXVJUOMHONVAEU-UHFFFAOYSA-N 1-(3-imidazol-1-ylpropyl)-5-phenylimidazolidine-2,4-dione Chemical compound C=1C=CC=CC=1C1C(=O)NC(=O)N1CCCN1C=CN=C1 XXVJUOMHONVAEU-UHFFFAOYSA-N 0.000 claims 1
- BFAULAUMYNQZCW-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-3-methyl-5-phenylimidazolidine-2,4-dione Chemical compound C=1C=C2N=CNC2=CC=1N1C(=O)N(C)C(=O)C1C1=CC=CC=C1 BFAULAUMYNQZCW-UHFFFAOYSA-N 0.000 claims 1
- NGJZDGZTGWZQHU-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-4-sulfanylidene-5-(2,3,4-trifluorophenyl)imidazolidin-2-one Chemical compound FC1=C(F)C(F)=CC=C1C1C(=S)NC(=O)N1C1=CC=C(NC=N2)C2=C1 NGJZDGZTGWZQHU-UHFFFAOYSA-N 0.000 claims 1
- BYZXAUWCXPMPDK-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(2,1,3-benzothiadiazol-5-yl)-2-sulfanylideneimidazolidin-4-one Chemical compound C1=C2NC=NC2=CC(N2C(=S)NC(C2C2=CC3=NSN=C3C=C2)=O)=C1 BYZXAUWCXPMPDK-UHFFFAOYSA-N 0.000 claims 1
- QNIMPEFZOBTPAU-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(2,1,3-benzothiadiazol-5-yl)imidazolidine-2,4-dione Chemical compound C1=C2NC=NC2=CC(N2C(=O)NC(C2C2=CC3=NSN=C3C=C2)=O)=C1 QNIMPEFZOBTPAU-UHFFFAOYSA-N 0.000 claims 1
- AZZFRDKXGUGTRC-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(2,3-difluoro-4-methylphenyl)-4-sulfanylideneimidazolidin-2-one Chemical compound FC1=C(F)C(C)=CC=C1C1C(=S)NC(=O)N1C1=CC=C(NC=N2)C2=C1 AZZFRDKXGUGTRC-UHFFFAOYSA-N 0.000 claims 1
- AJUGSLXCFBLQHE-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(2,3-dihydro-1,4-benzodioxin-6-yl)imidazolidine-2,4-dione Chemical compound C1=C2NC=NC2=CC(N2C(=O)NC(C2C=2C=C3OCCOC3=CC=2)=O)=C1 AJUGSLXCFBLQHE-UHFFFAOYSA-N 0.000 claims 1
- TXBCOCGENUWIHP-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(2-bromo-5-fluorophenyl)imidazolidine-2,4-dione Chemical compound FC1=CC=C(Br)C(C2C(NC(=O)N2C=2C=C3N=CNC3=CC=2)=O)=C1 TXBCOCGENUWIHP-UHFFFAOYSA-N 0.000 claims 1
- PHTVQKCBKDWZBY-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(2-chlorophenyl)imidazolidine-2,4-dione Chemical compound ClC1=CC=CC=C1C1C(=O)NC(=O)N1C1=CC=C(NC=N2)C2=C1 PHTVQKCBKDWZBY-UHFFFAOYSA-N 0.000 claims 1
- VNSPICHGRNGTIL-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(2-hydroxy-3-methoxyphenyl)imidazolidine-2,4-dione Chemical compound COC1=CC=CC(C2C(NC(=O)N2C=2C=C3N=CNC3=CC=2)=O)=C1O VNSPICHGRNGTIL-UHFFFAOYSA-N 0.000 claims 1
- NTNRIUAFBHODRG-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(2-hydroxy-5-methylphenyl)imidazolidine-2,4-dione Chemical compound CC1=CC=C(O)C(C2C(NC(=O)N2C=2C=C3N=CNC3=CC=2)=O)=C1 NTNRIUAFBHODRG-UHFFFAOYSA-N 0.000 claims 1
- WADYLOHJJCSTAF-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(3-chlorophenyl)imidazolidine-2,4-dione Chemical compound ClC1=CC=CC(C2C(NC(=O)N2C=2C=C3N=CNC3=CC=2)=O)=C1 WADYLOHJJCSTAF-UHFFFAOYSA-N 0.000 claims 1
- PDLPFLLSLKPGSQ-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(3-hydroxy-4-methoxyphenyl)-2-sulfanylideneimidazolidin-4-one Chemical compound C1=C(O)C(OC)=CC=C1C1C(=O)NC(=S)N1C1=CC=C(NC=N2)C2=C1 PDLPFLLSLKPGSQ-UHFFFAOYSA-N 0.000 claims 1
- JWLPLQZPWGTGDM-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(3-hydroxy-4-methoxyphenyl)imidazolidine-2,4-dione Chemical compound C1=C(O)C(OC)=CC=C1C1C(=O)NC(=O)N1C1=CC=C(NC=N2)C2=C1 JWLPLQZPWGTGDM-UHFFFAOYSA-N 0.000 claims 1
- CVLWWSXQLNSNGF-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(4-bromo-2-fluorophenyl)-4-sulfanylideneimidazolidin-2-one Chemical compound FC1=CC(Br)=CC=C1C1C(=S)NC(=O)N1C1=CC=C(N=CN2)C2=C1 CVLWWSXQLNSNGF-UHFFFAOYSA-N 0.000 claims 1
- JIVXZMFLCFNNBY-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(4-chloro-3-methylphenyl)-4-sulfanylideneimidazolidin-2-one Chemical compound C1=C(Cl)C(C)=CC(C2C(NC(=O)N2C=2C=C3N=CNC3=CC=2)=S)=C1 JIVXZMFLCFNNBY-UHFFFAOYSA-N 0.000 claims 1
- XPTXSMOWEGMJQC-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(4-chlorophenyl)-4-sulfanylideneimidazolidin-2-one Chemical compound C1=CC(Cl)=CC=C1C1C(=S)NC(=O)N1C1=CC=C(NC=N2)C2=C1 XPTXSMOWEGMJQC-UHFFFAOYSA-N 0.000 claims 1
- ROKHRVRZZBNKGJ-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(4-chlorophenyl)imidazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C1C(=O)NC(=O)N1C1=CC=C(NC=N2)C2=C1 ROKHRVRZZBNKGJ-UHFFFAOYSA-N 0.000 claims 1
- CEZNAXCARYIAEU-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(4-fluorophenyl)imidazolidine-2,4-dione Chemical compound C1=CC(F)=CC=C1C1C(=O)NC(=O)N1C1=CC=C(NC=N2)C2=C1 CEZNAXCARYIAEU-UHFFFAOYSA-N 0.000 claims 1
- JABHGIDIXZRVDN-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(4-phenylphenyl)-2-sulfanylideneimidazolidin-4-one Chemical compound O=C1NC(=S)N(C=2C=C3N=CNC3=CC=2)C1C(C=C1)=CC=C1C1=CC=CC=C1 JABHGIDIXZRVDN-UHFFFAOYSA-N 0.000 claims 1
- JPGWSJPHNNPVIP-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(4-phenylphenyl)-4-sulfanylideneimidazolidin-2-one Chemical compound C=1C=C2NC=NC2=CC=1N1C(=O)NC(=S)C1C(C=C1)=CC=C1C1=CC=CC=C1 JPGWSJPHNNPVIP-UHFFFAOYSA-N 0.000 claims 1
- HEXVNBQITIFOKU-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(4-phenylphenyl)imidazolidine-2,4-dione Chemical compound O=C1NC(=O)N(C=2C=C3N=CNC3=CC=2)C1C(C=C1)=CC=C1C1=CC=CC=C1 HEXVNBQITIFOKU-UHFFFAOYSA-N 0.000 claims 1
- GTFPAKYEYXNXOT-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-(4-propoxyphenyl)imidazolidine-2,4-dione Chemical compound C1=CC(OCCC)=CC=C1C1C(=O)NC(=O)N1C1=CC=C(NC=N2)C2=C1 GTFPAKYEYXNXOT-UHFFFAOYSA-N 0.000 claims 1
- SJNCPVKBIRFHDW-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-[3-fluoro-4-(trifluoromethyl)phenyl]imidazolidine-2,4-dione Chemical compound C1=C(C(F)(F)F)C(F)=CC(C2C(NC(=O)N2C=2C=C3N=CNC3=CC=2)=O)=C1 SJNCPVKBIRFHDW-UHFFFAOYSA-N 0.000 claims 1
- RERCJFJTRNJPCK-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-phenyl-2-sulfanylideneimidazolidin-4-one Chemical compound O=C1NC(=S)N(C=2C=C3N=CNC3=CC=2)C1C1=CC=CC=C1 RERCJFJTRNJPCK-UHFFFAOYSA-N 0.000 claims 1
- OBUJIRSEIQGFOA-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-phenyl-4-sulfanylideneimidazolidin-2-one Chemical compound C=1C=C2NC=NC2=CC=1N1C(=O)NC(=S)C1C1=CC=CC=C1 OBUJIRSEIQGFOA-UHFFFAOYSA-N 0.000 claims 1
- HZEIAWPYZBVCBW-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-phenylimidazolidine-2,4-dione Chemical compound O=C1NC(=O)N(C=2C=C3N=CNC3=CC=2)C1C1=CC=CC=C1 HZEIAWPYZBVCBW-UHFFFAOYSA-N 0.000 claims 1
- CTQKNEDJEFNYQB-UHFFFAOYSA-N 1-[3-(4-methylimidazol-1-yl)propyl]-5-phenylimidazolidine-2,4-dione Chemical compound C1=NC(C)=CN1CCCN1C(=O)NC(=O)C1C1=CC=CC=C1 CTQKNEDJEFNYQB-UHFFFAOYSA-N 0.000 claims 1
- AZUMTGCYMDJDNF-UHFFFAOYSA-N 1-[3-(5-methylimidazol-1-yl)propyl]-5-(4-phenylphenyl)imidazolidine-2,4-dione Chemical compound CC1=CN=CN1CCCN1C(=O)NC(=O)C1C1=CC=C(C=2C=CC=CC=2)C=C1 AZUMTGCYMDJDNF-UHFFFAOYSA-N 0.000 claims 1
- GWWDUADWWDASPW-UHFFFAOYSA-N 1-[3-(5-methylimidazol-1-yl)propyl]-5-(4-propoxyphenyl)imidazolidine-2,4-dione Chemical compound C1=CC(OCCC)=CC=C1C1C(=O)NC(=O)N1CCCN1C(C)=CN=C1 GWWDUADWWDASPW-UHFFFAOYSA-N 0.000 claims 1
- OPSHHCHDVHBYDN-UHFFFAOYSA-N 1-[3-(5-methylimidazol-1-yl)propyl]-5-phenylimidazolidine-2,4-dione Chemical compound CC1=CN=CN1CCCN1C(=O)NC(=O)C1C1=CC=CC=C1 OPSHHCHDVHBYDN-UHFFFAOYSA-N 0.000 claims 1
- PCDUJOHMIASDPO-UHFFFAOYSA-N 5-(2-bromo-4-fluorophenyl)-1-(3-imidazol-1-ylpropyl)imidazolidine-2,4-dione Chemical compound BrC1=CC(F)=CC=C1C1C(=O)NC(=O)N1CCCN1C=NC=C1 PCDUJOHMIASDPO-UHFFFAOYSA-N 0.000 claims 1
- UAVLGYVVXXRTQG-UHFFFAOYSA-N 5-(2-bromo-5-fluorophenyl)-1-[3-(5-methylimidazol-1-yl)propyl]imidazolidine-2,4-dione Chemical compound CC1=CN=CN1CCCN1C(=O)NC(=O)C1C1=CC(F)=CC=C1Br UAVLGYVVXXRTQG-UHFFFAOYSA-N 0.000 claims 1
- OTCASTOVNBEOFF-UHFFFAOYSA-N 5-(3-chlorophenyl)-1-(3-imidazol-1-ylpropyl)imidazolidine-2,4-dione Chemical compound ClC1=CC=CC(C2C(NC(=O)N2CCCN2C=NC=C2)=O)=C1 OTCASTOVNBEOFF-UHFFFAOYSA-N 0.000 claims 1
- KHKSQQSDCSHFKY-UHFFFAOYSA-N 5-(3-chlorophenyl)-1-[3-(4-methylimidazol-1-yl)propyl]imidazolidine-2,4-dione Chemical compound C1=NC(C)=CN1CCCN1C(=O)NC(=O)C1C1=CC=CC(Cl)=C1 KHKSQQSDCSHFKY-UHFFFAOYSA-N 0.000 claims 1
- RSDWKCTYUQMJCJ-UHFFFAOYSA-N 5-(3-chlorophenyl)-1-[3-(5-methylimidazol-1-yl)propyl]imidazolidine-2,4-dione Chemical compound CC1=CN=CN1CCCN1C(=O)NC(=O)C1C1=CC=CC(Cl)=C1 RSDWKCTYUQMJCJ-UHFFFAOYSA-N 0.000 claims 1
- FPHHWBQEXLHUNV-UHFFFAOYSA-N 5-[3-fluoro-4-(trifluoromethyl)phenyl]-1-(3-imidazol-1-ylpropyl)imidazolidine-2,4-dione Chemical compound C1=C(C(F)(F)F)C(F)=CC(C2C(NC(=O)N2CCCN2C=NC=C2)=O)=C1 FPHHWBQEXLHUNV-UHFFFAOYSA-N 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101710144961 Interferon tau-1 Proteins 0.000 claims 1
- 101710144950 Interferon tau-2 Proteins 0.000 claims 1
- 101710144962 Interferon tau-3 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 229940082332 Muscarinic M1 receptor antagonist Drugs 0.000 claims 1
- 108010008881 NBI 5788 Proteins 0.000 claims 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 102100031674 Protein-L-isoaspartate(D-aspartate) O-methyltransferase Human genes 0.000 claims 1
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 claims 1
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 claims 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 1
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 229940035678 anti-parkinson drug Drugs 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 229940002658 differin Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 150000002466 imines Chemical class 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 108700027921 interferon tau Proteins 0.000 claims 1
- 229940028885 interleukin-4 Drugs 0.000 claims 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 1
- 239000000234 muscarinic M1 receptor antagonist Substances 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 229940005654 nitrite ion Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 235000010288 sodium nitrite Nutrition 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 108010018276 trimethylguanosine synthase Proteins 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 229960002491 ibudilast Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 2
- KPWYNAGOBXLMSE-UHFFFAOYSA-N Tipelukast Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1SCCCOC1=CC=C(C(C)=O)C(OCCCC(O)=O)=C1CCC KPWYNAGOBXLMSE-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- XGXOSJSGDNPEEF-NRFANRHFSA-N dsstox_cid_27291 Chemical compound N([C@@H]1N=C(C=2C=3N(C1=O)CCC=3C=C(C=2)N)C=1C=CC=CC=1)C(=O)C1=CC=CN=C1 XGXOSJSGDNPEEF-NRFANRHFSA-N 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 229920002721 polycyanoacrylate Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229950004996 tipelukast Drugs 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- CRYXXTXWUCPIMU-WNQIDUERSA-N (2s)-2-aminobutanediamide;phenol Chemical compound OC1=CC=CC=C1.NC(=O)[C@@H](N)CC(N)=O CRYXXTXWUCPIMU-WNQIDUERSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- IPUJXWMHZRFSAT-UHFFFAOYSA-N 1-cyclopentyl-3-ethyl-6-(2-methylphenyl)-4,5-dihydropyrazolo[3,4-c]pyridin-7-one Chemical compound C1CN(C=2C(=CC=CC=2)C)C(=O)C2=C1C(CC)=NN2C1CCCC1 IPUJXWMHZRFSAT-UHFFFAOYSA-N 0.000 description 1
- VXYDHPDQMSVQCU-UHFFFAOYSA-N 2-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)piperidin-1-yl]-n-hydroxyacetamide Chemical compound COC1=CC=C(C2(CCN(CC(=O)NO)CC2)C#N)C=C1OC1CCCC1 VXYDHPDQMSVQCU-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- OPJKGTJXHVPYIM-UHFFFAOYSA-N 2-methylprop-2-enamide;phenol Chemical compound CC(=C)C(N)=O.OC1=CC=CC=C1 OPJKGTJXHVPYIM-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 1
- WFRXSXUDWCVSPI-UHFFFAOYSA-N 3h-benzimidazol-5-amine Chemical compound NC1=CC=C2NC=NC2=C1 WFRXSXUDWCVSPI-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- FUEJLKOVULHHHR-UHFFFAOYSA-N 4-methyliminoimidazolidin-2-one Chemical compound CN=C1NC(NC1)=O FUEJLKOVULHHHR-UHFFFAOYSA-N 0.000 description 1
- XDBHURGONHZNJF-UHFFFAOYSA-N 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2N=C(C=CC=2)C(O)=O)=CS1 XDBHURGONHZNJF-UHFFFAOYSA-N 0.000 description 1
- 101150015280 Cel gene Proteins 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- DHCOPPHTVOXDKU-UHFFFAOYSA-N Tofimilast Chemical compound C1CN2C(C=3SC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 DHCOPPHTVOXDKU-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960001403 clobazam Drugs 0.000 description 1
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- OPQRBXUBWHDHPQ-UHFFFAOYSA-N etazolate Chemical compound CCOC(=O)C1=CN=C2N(CC)N=CC2=C1NN=C(C)C OPQRBXUBWHDHPQ-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229960004930 fludiazepam Drugs 0.000 description 1
- ROYOYTLGDLIGBX-UHFFFAOYSA-N fludiazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ROYOYTLGDLIGBX-UHFFFAOYSA-N 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- ZRKSVHFXTRFQFL-UHFFFAOYSA-N isocyanomethane Chemical compound C[N+]#[C-] ZRKSVHFXTRFQFL-UHFFFAOYSA-N 0.000 description 1
- 150000002527 isonitriles Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- CFRXVFRHMZLQBS-UHFFFAOYSA-N n-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-6-(difluoromethoxy)-[1]benzofuro[3,2-c]pyridine-9-carboxamide Chemical compound ClC1=CN(O)C=C(Cl)C1=NC(=O)C1=CC=C(OC(F)F)C2=C1C1=CN=CC=C1O2 CFRXVFRHMZLQBS-UHFFFAOYSA-N 0.000 description 1
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 1
- JERXUPDBWDWFCF-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]pyrrolo[2,3-b]pyridin-3-yl]-2-oxoacetamide Chemical compound C1=CC(F)=CC=C1CN1C2=NC=CC=C2C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)=C1 JERXUPDBWDWFCF-UHFFFAOYSA-N 0.000 description 1
- FSBLVBBRXSCOKU-UHFFFAOYSA-N n-butyl isocyanide Chemical compound CCCC[N+]#[C-] FSBLVBBRXSCOKU-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 239000002658 neuropeptide Y receptor agonist Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical group COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 description 1
- 229950000505 tandospirone Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229950002896 tetomilast Drugs 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229950003899 tofimilast Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9411808P | 2008-09-04 | 2008-09-04 | |
| US61/094,118 | 2008-09-04 | ||
| PCT/EP2009/061453 WO2010026212A1 (en) | 2008-09-04 | 2009-09-04 | Novel inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012502006A JP2012502006A (ja) | 2012-01-26 |
| JP2012502006A5 true JP2012502006A5 (OSRAM) | 2012-10-18 |
| JP5707327B2 JP5707327B2 (ja) | 2015-04-30 |
Family
ID=41278686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011525556A Active JP5707327B2 (ja) | 2008-09-04 | 2009-09-04 | 新規の阻害剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8962860B2 (OSRAM) |
| EP (1) | EP2344157B1 (OSRAM) |
| JP (1) | JP5707327B2 (OSRAM) |
| KR (1) | KR101694556B1 (OSRAM) |
| CN (1) | CN102186475B (OSRAM) |
| AU (1) | AU2009289238B2 (OSRAM) |
| BR (1) | BRPI0918564B1 (OSRAM) |
| CA (1) | CA2735795C (OSRAM) |
| DK (1) | DK2344157T3 (OSRAM) |
| EA (1) | EA021150B1 (OSRAM) |
| ES (1) | ES2599621T3 (OSRAM) |
| IL (1) | IL211018A (OSRAM) |
| MX (1) | MX2011002106A (OSRAM) |
| NZ (1) | NZ591531A (OSRAM) |
| SG (1) | SG193828A1 (OSRAM) |
| WO (1) | WO2010026212A1 (OSRAM) |
| ZA (1) | ZA201100898B (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2344158B1 (en) * | 2008-09-04 | 2017-12-27 | Probiodrug AG | Use of isoqc inhibitors |
| ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
| WO2011076854A1 (en) | 2009-12-22 | 2011-06-30 | Probiodrug Ag | CLEAVAGE OF β-AMYLOID PRECURSOR PROTEIN |
| US8530670B2 (en) * | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| SG194770A1 (en) | 2011-05-27 | 2013-12-30 | Probiodrug Ag | Radiolabelled glutaminyl cyclase inhibitors |
| WO2014140279A1 (en) | 2013-03-15 | 2014-09-18 | Probiodrug Ag | Novel inhibitors |
| EP3234611A1 (en) | 2014-12-19 | 2017-10-25 | Probiodrug AG | Novel method for the detection of pglu-abeta peptides |
| CN108658869A (zh) * | 2017-03-29 | 2018-10-16 | 复旦大学 | 具有抗肿瘤活性的化合物及其制备方法和在制药中的用途 |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| RU2665633C1 (ru) * | 2017-05-26 | 2018-09-03 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Новый ингибитор глутаминилциклаз и его применение |
| RU2662559C1 (ru) * | 2017-10-27 | 2018-07-26 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Новый ингибитор глутаминилциклаз и его применение для лечения заболеваний легких и дыхательных путей |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| EP3521308B1 (en) | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
| US11958871B2 (en) * | 2018-02-23 | 2024-04-16 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases |
| TWI715156B (zh) | 2018-08-31 | 2021-01-01 | 財團法人國家衛生研究院 | 苯并咪唑化合物及其用於治療阿茲海默症或亨丁頓氏症之用途 |
| JP7565609B2 (ja) * | 2019-05-24 | 2024-10-11 | エモリー ユニバーシティー | アスパラギンエンドペプチダーゼ（ａｅｐ）阻害剤、それに関連する組成物および使用 |
| BR112022000505A8 (pt) * | 2019-07-12 | 2022-04-12 | Scenic Immunology B V | Compostos de 3,4-(anel fundido em 5)-5-fenil-pirrolidin-2-ona n-substituídos como inibidores de enzima isoqc e/ou qc |
| CA3221003A1 (en) * | 2021-06-24 | 2022-12-29 | Insilico Medicine Ip Limited | Beta-lactam derivatives for the treatment of diseases |
| WO2025021012A1 (en) * | 2023-07-21 | 2025-01-30 | Insilico Medicine Ip Limited | Crystalline beta-lactam derivatives and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD293584A5 (de) * | 1990-03-23 | 1991-09-05 | Adw,Zi Fuer Organische Chemie,De | Verfahren zur herstellung von neuen 3,5,5-trisubstituierten 1-(benzimidazol-2-yl)-imidazolidin-2,4-dionen bzw. -4-on-2-thionen |
| DE4320432A1 (de) * | 1993-06-21 | 1994-12-22 | Bayer Ag | Substituierte Mono- und Bipyridylmethylderivate |
| US20040006011A1 (en) * | 1996-07-12 | 2004-01-08 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| HUP0002037A3 (en) | 1997-07-31 | 2001-07-30 | Abbott Lab | Hydroximic acid derivatives, use of them for producing pharmaceutical compositions suitable for inhibiting matrix metalloproteinas and pharmaceutical compositions containing the compounds |
| US6235786B1 (en) * | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
| US7371871B2 (en) * | 2003-05-05 | 2008-05-13 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| KR101099206B1 (ko) | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
| WO2008028032A2 (en) | 2006-09-01 | 2008-03-06 | Allergan, Inc. | Therapeutic substituted hydantoins and related compounds |
| US20080249083A1 (en) * | 2006-09-21 | 2008-10-09 | Probiodrug Ag | Novel genes related to glutaminyl cyclase |
| JP5456479B2 (ja) * | 2006-11-09 | 2014-03-26 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| CN101519376B (zh) * | 2008-02-27 | 2012-10-10 | 上海药明康德新药开发有限公司 | 一种芳香环双酰胺螺环类药物模板的合成方法 |
| EP2344158B1 (en) * | 2008-09-04 | 2017-12-27 | Probiodrug AG | Use of isoqc inhibitors |
-
2009
- 2009-09-04 EP EP09782605.1A patent/EP2344157B1/en active Active
- 2009-09-04 NZ NZ591531A patent/NZ591531A/en unknown
- 2009-09-04 EA EA201100424A patent/EA021150B1/ru not_active IP Right Cessation
- 2009-09-04 BR BRPI0918564-0A patent/BRPI0918564B1/pt active IP Right Grant
- 2009-09-04 WO PCT/EP2009/061453 patent/WO2010026212A1/en not_active Ceased
- 2009-09-04 ES ES09782605.1T patent/ES2599621T3/es active Active
- 2009-09-04 US US12/554,611 patent/US8962860B2/en active Active
- 2009-09-04 AU AU2009289238A patent/AU2009289238B2/en active Active
- 2009-09-04 SG SG2013064738A patent/SG193828A1/en unknown
- 2009-09-04 CN CN200980139148.0A patent/CN102186475B/zh active Active
- 2009-09-04 MX MX2011002106A patent/MX2011002106A/es active IP Right Grant
- 2009-09-04 DK DK09782605.1T patent/DK2344157T3/en active
- 2009-09-04 KR KR1020117007403A patent/KR101694556B1/ko active Active
- 2009-09-04 CA CA2735795A patent/CA2735795C/en active Active
- 2009-09-04 JP JP2011525556A patent/JP5707327B2/ja active Active
-
2011
- 2011-02-02 IL IL211018A patent/IL211018A/en active IP Right Grant
- 2011-02-03 ZA ZA2011/00898A patent/ZA201100898B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502006A5 (OSRAM) | ||
| JP2022110130A (ja) | 新規の阻害剤 | |
| JP5487214B2 (ja) | キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物 | |
| JP5180099B2 (ja) | 置換イミダゾール誘導体、組成物ならびにｐｔｐアーゼ阻害剤としての使用方法 | |
| JP5798157B2 (ja) | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 | |
| KR101214665B1 (ko) | 트리아졸 유도체 또는 그의 염 | |
| JP6026284B2 (ja) | グルタミニルシクラーゼの阻害剤 | |
| CA2714058A1 (en) | 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease | |
| KR20120016676A (ko) | 우레이도페닐치환 트리아진 유도체와 이들의 치료적 용도 | |
| JP2010524893A5 (OSRAM) | ||
| JP2020512373A5 (OSRAM) | ||
| JP5930573B2 (ja) | グルタミニルシクラーゼ阻害剤の新規使用 | |
| AU2023212015B2 (en) | Pyrrolidine compounds | |
| HRP20041008A2 (en) | Triazole derivatives as tachykinin receptor antagonists | |
| AU2014348422B2 (en) | EBNA1 inhibitors and their method of use | |
| CZ20023264A3 (cs) | Deriváty oxazolu, způsob jejich výroby a použití a farmaceutický prostředek | |
| JP2010524899A5 (OSRAM) | ||
| WO2007105753A1 (ja) | トリアゾール誘導体またはその塩 | |
| KR20120034726A (ko) | 트리아진 유도체와 이들의 치료적 용도 | |
| KR20120026612A (ko) | 벤질 치환 트리아진 유도체와 이들의 치료적 용도 | |
| JP2004516295A5 (OSRAM) | ||
| TW200920356A (en) | Aminoalkylazole derivatives as histamine-3 antagonists | |
| KR20120026613A (ko) | 스티릴-트리아진 유도체와 이들의 치료적 용도 | |
| AU729341B2 (en) | Hydantoin derivatives having an inhibitory activity for farnesyl transferase | |
| CN102573480B (zh) | 三嗪衍生物及其治疗应用 |